Dr. Kausik Ray and Dr. C. Michael Gibson Discuss: Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent – Results of the Phase 3 ORION-11 trial – Sponsored by an independent educational grant from The Medicines Company